Coya Therapeutics, Inc. (COYA)
(Real Time Quote from BATS)
$7.36 USD
+0.12 (1.66%)
Updated Jul 30, 2024 10:20 AM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
COYA 7.36 +0.12(1.66%)
Will COYA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for COYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COYA
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS
Here's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep going
COYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
Other News for COYA
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
Coya Therapeutics expands sponsored research collaboration with HMRI
Eli Lilly And Alzheimer's Disease: The Paucity Of Progress
Analysts Are Bullish on These Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Protagonist Therapeutics (PTGX)
Coya Therapeutics files to sell 603K common shares for holders